-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Cogent Biosciences (NASDAQ:COGT) & Abliva AB (Publ) (OTCMKTS:NEVPF) Financial Review
Cogent Biosciences (NASDAQ:COGT) & Abliva AB (Publ) (OTCMKTS:NEVPF) Financial Review
Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and Cogent Biosciences (NASDAQ:COGT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Abliva AB (publ) and Cogent Biosciences, as reported by MarketBeat.com.
Get Abliva AB (publ) alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abliva AB (publ) | 0 | 0 | 0 | 0 | N/A |
| Cogent Biosciences | 0 | 0 | 3 | 0 | 3.00 |
Cogent Biosciences has a consensus target price of $21.33, indicating a potential upside of 46.02%. Given Cogent Biosciences' higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Abliva AB (publ).
Profitability
This table compares Abliva AB (publ) and Cogent Biosciences' net margins, return on equity and return on assets.| Net Margins | Return on Equity | Return on Assets | |
| Abliva AB (publ) | N/A | -159.15% | -120.99% |
| Cogent Biosciences | N/A | -73.27% | -42.95% |
Valuation and Earnings
This table compares Abliva AB (publ) and Cogent Biosciences' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abliva AB (publ) | $20,000.00 | 674.18 | -$14.40 million | ($0.04) | -1.25 |
| Cogent Biosciences | $7.87 million | 85.06 | -$72.27 million | ($2.48) | -5.89 |
Abliva AB (publ) has higher earnings, but lower revenue than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Abliva AB (publ), indicating that it is currently the more affordable of the two stocks.
Summary
Cogent Biosciences beats Abliva AB (publ) on 5 of the 9 factors compared between the two stocks.
About Abliva AB (publ)
(Get Rating)
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
About Cogent Biosciences
(Get Rating)
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and Cogent Biosciences (NASDAQ:COGT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Abliva AB(Publ)(OTCMKTS：NEVPF-GET Rating)和Cogent Biosciences(纳斯达克：COGT-GET Rating)都是小盘医疗公司，但哪只股票更优越？我们将根据分析师推荐的收益、股息、机构所有权、风险、盈利能力和估值对这两家公司进行对比。
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and price targets for Abliva AB (publ) and Cogent Biosciences, as reported by MarketBeat.com.
据MarketBeat.com报道，这是Abliva AB(Publ)和Cogent Biosciences最近的评级和目标价细分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abliva AB (publ) | 0 | 0 | 0 | 0 | N/A |
| Cogent Biosciences | 0 | 0 | 3 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Abliva AB(酒吧) | 0 | 0 | 0 | 0 | 不适用 |
| 令人信服的生物科学 | 0 | 0 | 3 | 0 | 3.00 |
Cogent Biosciences has a consensus target price of $21.33, indicating a potential upside of 46.02%. Given Cogent Biosciences' higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Abliva AB (publ).
Coent Biosciences的共识目标价为21.33美元，表明潜在涨幅为46.02%。鉴于Cogent Biosciences更有可能上行，分析师们显然认为Cogent Biosciences比Abliva AB(Publ)更有利。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Abliva AB (publ) | N/A | -159.15% | -120.99% |
| Cogent Biosciences | N/A | -73.27% | -42.95% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Abliva AB(酒吧) | 不适用 | -159.15% | -120.99% |
| 令人信服的生物科学 | 不适用 | -73.27% | -42.95% |
Valuation and Earnings
估值和收益
This table compares Abliva AB (publ) and Cogent Biosciences' revenue, earnings per share (EPS) and valuation.
此表比较了Abliva AB(Publ)和Cogent Biosciences的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abliva AB (publ) | $20,000.00 | 674.18 | -$14.40 million | ($0.04) | -1.25 |
| Cogent Biosciences | $7.87 million | 85.06 | -$72.27 million | ($2.48) | -5.89 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Abliva AB(酒吧) | $20,000.00 | 674.18 | -1,440万美元 | ($0.04) | -1.25 |
| 令人信服的生物科学 | 787万美元 | 85.06 | -7,227万元 | ($2.48) | -5.89 |
Abliva AB (publ) has higher earnings, but lower revenue than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Abliva AB (publ), indicating that it is currently the more affordable of the two stocks.
Abliva AB(Publ)的收益比Cogent Biosciences高，但收入低。Coent Biosciences的市盈率低于Abliva AB(Publ)，这表明它目前是两只股票中更负担得起的一只。
Summary
摘要
Cogent Biosciences beats Abliva AB (publ) on 5 of the 9 factors compared between the two stocks.
在两只股票之间的9个因素中，有5个因素的表现优于Abliva AB(Publ)。
About Abliva AB (publ)
关于Abliva AB(Publ)
(Get Rating)
(获取评级)
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Abliva AB(Publ)开发治疗原发线粒体疾病的药物。该公司正在开发KL1333，它处于慢性治疗初级线粒体疾病的2/3阶段临床试验；NV354，正在准备治疗复杂I缺乏的初级线粒体疾病的临床试验；以及NeuroSTAT，处于创伤性脑损伤的1b/2a阶段临床研究。它与异构酶、永进制药、宾夕法尼亚大学、费城儿童医院和奥罗博罗斯仪器公司达成了合作协议。该公司前身为NeuroVive Pharmtics AB(Publ)，并于2020年5月更名为Abliva AB(Publ)。Abliva AB(Publ)成立于2000年，总部设在瑞典隆德。
About Cogent Biosciences
关于Cogent Bioscions
(Get Rating)
(获取评级)
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Cogent Biosciences，Inc.是一家生物技术公司，专注于为基因定义的疾病开发精确疗法。它的主要候选产品包括CGT9486，一种选择性酪氨酸激酶抑制剂，旨在抑制导致系统性肥大细胞增多的KIT D816V突变，以及KIT外显子17的其他突变，这些突变在晚期胃肠道间质瘤患者中发现。它与Plexxikon Inc.就贝祖拉替尼的研究、开发和商业化达成了一项许可协议。该公司前身为Unum治疗公司，并于2020年10月更名为Cogent Biosciences，Inc.。Coent Biosciences，Inc.成立于2014年，总部位于马萨诸塞州剑桥市。
Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Abliva AB(Publ)日报的新闻和评级-在下面输入您的电子邮件地址，以通过MarketBeat.com的免费每日电子邮件时事通讯接收对Abliva AB(Publ)和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧